Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct platform to automate critical microbiology quality control testing.
Rapid Micro Biosystems, a life sciences technology company, has announced that Samsung Biologics has selected the Growth Direct (registered trademark) platform to automate its microbial quality control processes to deliver increased efficiency, more robust data integrity and scalable quality control operations.
The Growth Direct improves operational efficiency and data integrity in the quality control microbiology lab
Robert Spignesi, President and CEO of Rapid Micro Biosystems, said: “Samsung Biologics is a leading global contract development and manufacturing organisation (CDMO) and has demonstrated an unwavering commitment to automation and quality management in biopharmaceutical manufacturing. The Growth Direct improves operational efficiency and data integrity in the quality control microbiology lab, and we are proud to partner with Samsung Biologics.”
Global pharmaceutical manufacturers rely on the Growth Direct platform to meet both today’s microbiological quality control standards and tomorrow’s challenges.
The Growth Direct platform is the only fully automated, non-destructive growth-based platform for microbiology quality control testing that offers faster time to results, improved data integrity, and enhanced accuracy, with greater sample capacity.
